Solu Therapeutics
Solu Therapeutics is a biotechnology company developing therapies to eliminate disease-driving cells in various therapeutic areas. They utilize proprietary CyTAC and TicTAC platforms to create targeted therapies, with their lead product candidate, STX-0712, currently in Phase 1 clinical trials for hematologic malignancies.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $41M
Date: 09-Apr-2025
Investors: Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital (HgC), The Leukemia & Lymphoma Society Therapy Acceleration Program, Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management, Alexandria Venture Investments
Markets: Biotechnology, Oncology, Immunology
HQ: Boston, Massachusetts, United States
Founded: 2022
Website: https://www.solutherapeutics.com
LinkedIn: https://www.linkedin.com/company/solu-therapeutics
Twitter: https://twitter.com/Solu_Tx
Crunchbase: https://www.crunchbase.com/organization/solu-therapeutics
Leave a Comment
Comments
No comments yet.